【重磅】华领医药大爆发!业绩期首次实现盈利,核心产品销量、营收双双翻倍

米内网
Aug 30, 2025

2025年,对于华领医药(02552.HK)而言注定是一个被写进公司发展史的重要年份。上半年,公司交出了一份里程碑式的成绩单,核心产品葡萄糖激酶激活剂(GKA)华堂宁®(多格列艾汀片)在自主商业化模式下实现销量和营收双双翻倍。同时,华领医药在业绩期内首次实现盈利。此次盈利的背后,既有与拜耳终止协议后一次性递延收入的贡献,更重要的是华堂宁®自主商业化所带来的强劲内生增长,标志着华领医药正在从一个聚焦...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10